Centers for Disease Control and Prevention
- CDC Latest Updates
- CDC Guidance: COVID-19 Vaccination Considerations for Persons with Underlying Medical Conditions [December 26]
- CDC Update on COVID-19 Vaccines and Severe Allergic Reactions [December 19]
- Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2 Infection Using Symptom Monitoring and Diagnostic Testing [December 2] Read More.
- CDC Advisory Committee on Immunization Practices Recommendations for COVID-19 Vaccine Roll-Out [December 1] View Meeting Presentations
- CDC Updates Guidance on Celebrating Thanksgiving [Novembre 19]
- Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 Experimental and epidemiological data support community masking to reduce the spread of SARS-CoV-2. The prevention benefit of masking is derived from the combination of source control and personal protection for the mask wearer. The relationship between source control and personal protection is likely complementary and possibly synergistic14, so that individual benefit increases with increasing community mask use. Further research is needed to expand the evidence base for the protective effect of cloth masks and in particular to identify the combinations of materials that maximize both their blocking and filtering effectiveness, as well as fit, comfort, durability, and consumer appeal. Adopting universal masking policies can help avert future lockdowns, especially if combined with other non-pharmaceutical interventions such as social distancing, hand hygiene, and adequate ventilation. [November 10]
- CDC Expands Definition of Who Is in “Close Contact” of an Individual with COVID-19 [October 21]
- CDC Morbidity and Mortality Weekly Report: Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020 [October 20]
- Wear Face Masks on Public Transportation Conveyances and at Transportation Hubs [October 20]
- CDC Morbidity and Mortality Weekly Report: Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020 [October 16]
- How COVID-19 Spreads “Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission” [October 5]
- Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020 Morbidity and Mortality Weekly Report. [September 10]
- CDC Updates Guidance on Testing for COVID-19 Access the most up-to-date guidance information
- Morbidity and Mortality Weekly Report; Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020 [August 31]
- Information for Pediatric Healthcare Providers. Revisions were made on August 14, 2020 to reflect new evidence about COVID-19 in children. [August 19]
- When to Quarantine? [Updated August 16]
- Duration of Isolation and Precautions for Adults with COVID-19 [Updated August 16]
- Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020 [July 24]
- Duration of Isolation and Precautions for Adults with COVID-19 [July 22]
- Considerations for Release of Stockpiled N95s Beyond the Manufacturer-Designated Shelf Life [July 20]
- Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance) [July 17]
- Criteria for Return to Work for Healthcare Personnel with SARS-CoV-2 Infection (Interim Guidance) [July 17]
- Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center — Boston, Massachusetts, 2020 [July 10]
- Clinical Questions about COVID-19 Questions and Answers [July 7]
- CDC Updates, Expands List of People at Risk of Severe COVID-19 Illness [June 25]
- COVID-19 in Racial and Ethnic Minority Groups [June 25]
- Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19
- Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020 [June 30]
- Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 [June 15]
- Considerations for Events and Gatherings [June 12]
- Using Telehealth to Expand Access to Essential Health Services during the COVID-19 Pandemic [June10]
- GUIDELINES: OPENING UP AMERICA AGAIN [April 16]
- Helping Communities Plan and Respond: Communities, Schools, Workplaces, and Events
- Symptoms
- Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Setting
- Criteria for Return to Work for Healthcare Personnel with Suspected or Confirmed COVID-19 (Interim Guidance)
- Guidance for U.S. Healthcare Facilities about Coronavirus (COVID-19)
- Strategies to Optimize the Supply of PPE and Equipment
- Strategies for Optimizing the Supply of N95 Respirators
- Strategies to Mitigate Healthcare Personnel Staffing Shortages
- Information for Pediatric Healthcare Providers
- Healthcare Infection Prevention and Control FAQs for COVID-19
- Clinical Questions about COVID-19: Questions and Answers
- Healthcare Infection Prevention and Control FAQs
- Healthcare Provider and Facility Operational Considerations for Non-US Settings
- Training for Healthcare Professionals
- Resources for Hospitals and Healthcare Professionals Preparing for Patients with Suspected or Confirmed COVID-19
- Decontamination and Reuse of Filtering Facepiece Respirators using Contingency and Crisis Capacity Strategies
- Reopening Guidance for Cleaning and Disinfecting Public Spaces, Workplaces, Businesses, Schools, and Homes
- SPHERES A National Open Genomics Consortium for the COVID-19 Response
- [May 29] Evidence for Limited Early Spread of COVID-19 Within the United States, January–February 2020
- [June 3] Impact of the COVID-19 Pandemic on Emergency Department Visits — United States, January 1, 2019–May 30, 2020
Centers for Medicare & Medicaid Services
- [May 29] CMS Releases Updated COVID-19 Medicare Fee-for-Service Billing FAQ Document CMS shared new and updated answers to Frequently Asked Questions (FAQs) to supplement previously released guidance on Medicare billing during the COVID-19 pandemic. The new FAQs address telehealth telephone-only service codes, guidance on how to bill if video is disconnected during a telehealth visit, and beneficiary consent requirements for telehealth services. The policies included in this FAQ are effective for the duration of the public health emergency.
- CMS Expands Telehealth Services for Medicare Advantage Beneficiaries On May 22, the Centers for Medicare & Medicaid Services released a final rule that encourages Medicare Advantage (MA) plans to increase their telehealth benefits and plan options for beneficiaries in rural areas. Under the rule, MA plans will have more flexibility to count telehealth providers in certain specialty areas, including otolaryngology, toward meeting CMS network adequacy standards. The telehealth provisions in the rule are effective beginning January 1, 2021. An agency fact sheet describing the rule is available on the CMS website.
- Toolkit on State Actions to Mitigate COVID-19 Prevalence in Nursing Homes [June1]
- COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing [Updated May 27]
- Re-opening Facilities to Provide Non-emergent Non-COVID-19 Healthcare: Phase I [April 19]
- Press Release: CMS Issues Recommendations to Re-Open Health Care Systems in Areas with Low Incidence of COVID-19 [April 19]
- Administration Issues Second Round of Sweeping Changes to Support U.S. Healthcare System During COVID-19 Pandemic [April 30]
- CMS issued Frequently Asked Questions (FAQs) clarifying requirements and considerations for hospitals and other providers related to the Emergency Medical Treatment and Labor Act (EMTALA) [April 30]
- COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers [April 29]
- Quality Payment Program – COVID-19 Response [Updated April 29]
- COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing [Updated April 29]
- COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing [April 17]
- CMS Increases Medicare Payment for High-Production Coronavirus Lab Tests [April 16]
- Administration Announces Expanded Coverage for Essential Diagnostic Services Amid COVID-19 Public Health Emergency [April 13]
- CMS Issues Updated Recommendations on Non-Emergent, Elective Medical Services and Treatment [April 6]
- CMS Addresses Physician Financial Stability and Offers More Flexibility on Telehealth [April 6]
- Administration Makes Sweeping Regulatory Changes to Help U.S. Healthcare System Address COVID-19 Patient Surge [March 30]
- Announces Accelerated and Advanced Medicare Payments to Provide Emergency Funding [March 29]
- Announces Delay for Clinicians Participating in Quality Reporting Programs in Response to COVID-19 with Explanation to AAO-HNS Members and Additional Resources [March 22]
Food and Drug Administration
- FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines [January 4]
- FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine [December 18]
- FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine [December 11]
- [December 10] VRBPAC Votes in Favor of Emergency Use Authorization for Pfizer/BioNTech COVID-19 Vaccine On December 10 the Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened at an all-day meeting to consider whether the COVID-19 vaccine developed by Pfizer, Inc. in partnership with BioNTech Manufacturing GmbH merits an emergency use authorization (EUA) by the Food and Drug Administration (FDA). The VRBPAC has voted in favor of the EUA. If the FDA follows the VRBPAC guidance, which most expect the agency to do, it will speed up the delivery of the first COVID-19 vaccinations in the United States. Some experts estimate the vaccine’s rollout could commence within a matter of days. Read More.
- FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 [November 21]
- FDA Authorizes First COVID-19 Test for Self-Testing at Home [November 17]
- FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 [November 9]
- FDA Approves First Treatment for COVID-19 [October 22]
- FDA launched a new vaccines webpage to highlight new information as it becomes available. The new page includes the October 6 FDA issued guidance with recommendations for vaccine sponsors regarding the scientific data and information that would support issuance of an emergency use authorization (EUA) for investigational vaccines intended to prevent COVID-19.
- FDA Authorizes First Point-of-Care Antibody Test for COVID-19 [October 6]
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency [September 21]
- FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 [August 28]
- FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic [August 23]
- FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing [August 15]
- Medical Device Shortages During the COVID-19 Public Health Emergency [August 14]
- FDA Authorizes First Two Tests that Estimate a Patient’s Antibodies from Past SARS-CoV-2 Infection [July 31]
- Hand Sanitizers: FDA Updates on Recalls Due to Dangerous, Potential Presence of Methanol [July 25]
- FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing [July 18]
- FDA Issued Emergency Use Authorization for Point of Care Antigen Test [July 6]
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines [June 30]
- FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use [June 15]
- FDA Revokes Emergency Use Ruling for Hydroxychloroquine and Chloroquine Phosphate in Treating COVID-19 [June 15]
- FDA Takes Steps to Streamline Development of Tests with At-Home Sample Collection [May 29]
- FDA Provides New Tool to Aid Development and Evaluation of Diagnostic Tests That Detect SARS-CoV-2 Infection [May 27]
- The FDA issued an Emergency Use Authorization for the Stryker Sustainability Solutions (SSS) VHP N95 Respirator Decontamination System (RDS) [May 27]
- Certain Filtering Facepiece Respirators from China May Not Provide Adequate Respiratory Protection – Letter to Health Care Providers [May 7]
- Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens [May 8]
- Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy [May 4]
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment [May 1]
- FDA Includes Ventilator Developed by NASA in Ventilator Emergency Use Authorization [April 30]
- FDA Issues Emergency Use Authorization to Decontaminate Millions of N95 Respirators [April 13]
National Institutes of Health
- NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 Begins [October 8]
- The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Convalescent Plasma for the Treatment of COVID-19 [September 1]
- NIH Clinical Trail to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 [August 4]
- Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins [July 27]
- NIH Launches Clinical Trials Network to Test COVID-19 Vaccines and Other Prevention Tools [July 8]
- First Molecular Profiles of Severe COVID-19 Infections [June 9]
- Early results show benefit of remdesivir for COVID-19 [June 2]
- Peer-reviewed Data Shows Remdesivir for COVID-19 Improves Time to Recovery [May 22]
- Clinical Trial Testing Antiviral Remdesivir Plus Anti-inflammatory Drug Baricitinib for COVID-19 Begins [May 8]
- Study Finds Nearly Everyone Who Recovers From COVID-19 Makes Coronavirus Antibodies [May 7]
- NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [April 29]
- Expert U.S. Panel Develops NIH Treatment Guidelines for COVID-19 [April 21]
- NIH study validates decontamination methods for re-use of N95 respirators [April 15]
U.S. Department of Justice
- DEA Issues Exceptions to Regulations for DEA-registered Hospital/Clinics [April 13]
- DEA Exception for Signing an Invoice at the Time of Receipt of Controlled Substances at an Opioid Treatment Center (OTP) [April 13]
